At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 68 enrolled
Drug / intervention
RN564biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ESCALATING DOSES OF RN564 IN WOMEN WITH OSTEOPENIA AND IN HEALTHY MEN
In Brief
A Phase 1 clinical trial evaluating RN564 for Osteopenia and 2 related conditions. Completed, enrolled 68 participants across 8 sites.
Detailed Summary
The purpose of this study is to determine the safety and tolerability of RN564 in women with osteopenia and healthy men.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteopenia, Osteoporosis, Bone Disease
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 2011
Enrollment StartApr 2011
Primary CompletionMay 2012
TodayJul 2026
First PostedFeb 10, 2011
Enrollment StartApr 1, 2011
Primary CompletionMay 24, 2012
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 15.4 years ago
Interventions
RN564biological
Intravenous, single dose with experimental dose